Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
26
RNAZ Quote, Financials, Valuation and Earnings
Last price:
$8.59
Seasonality move
:
-30.19%
Day range:
$8.45 - $8.78
52-week range:
$6.15 - $468.44
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
5.05x
Volume:
3.3K
Avg. volume:
13K
1-year change:
-96.84%
Market cap:
$7.2M
Revenue:
--
EPS (TTM):
-$242.08
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RNAZ
TransCode Therapeutics, Inc.
|
-- | -$0.33 | -- | -98.73% | $10.00 |
|
AQST
Aquestive Therapeutics, Inc.
|
$12.9M | -$0.11 | 12.46% | -32.26% | $10.30 |
|
LLY
Eli Lilly & Co.
|
$16.1B | $5.89 | 30.84% | 53.75% | $1,056.70 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RNAZ
TransCode Therapeutics, Inc.
|
$8.64 | $10.00 | $7.2M | -- | $0.00 | 0% | -- |
|
AQST
Aquestive Therapeutics, Inc.
|
$6.44 | $10.30 | $785.7M | -- | $0.00 | 0% | 14.71x |
|
LLY
Eli Lilly & Co.
|
$1,014.49 | $1,056.70 | $908B | 50.17x | $1.50 | 0.59% | 15.57x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.09 | $0.85 | $137.4M | 1.83x | $0.80 | 0% | 2.12x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.24 | $7.00 | $8.2M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RNAZ
TransCode Therapeutics, Inc.
|
-- | 9.086 | -- | 0.96x |
|
AQST
Aquestive Therapeutics, Inc.
|
103.29% | 2.367 | 18.95% | 5.42x |
|
LLY
Eli Lilly & Co.
|
64.11% | -0.293 | 6.22% | 0.65x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RNAZ
TransCode Therapeutics, Inc.
|
-$4.8K | -$4.6M | -766.9% | -775.26% | -- | -$4.1M |
|
AQST
Aquestive Therapeutics, Inc.
|
$8.3M | -$11.5M | -91.28% | -- | -89.63% | -$12.9M |
|
LLY
Eli Lilly & Co.
|
$14.6B | $8.4B | 33.81% | 106.26% | 47.65% | $6B |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
TransCode Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns RNAZ or AQST?
Aquestive Therapeutics, Inc. has a net margin of -- compared to TransCode Therapeutics, Inc.'s net margin of -120.61%. TransCode Therapeutics, Inc.'s return on equity of -775.26% beat Aquestive Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RNAZTransCode Therapeutics, Inc.-- -$5.82 $1.4M AQSTAquestive Therapeutics, Inc.64.82% -$0.14 $124.8M -
What do Analysts Say About RNAZ or AQST?
TransCode Therapeutics, Inc. has a consensus price target of $10.00, signalling upside risk potential of 3142.35%. On the other hand Aquestive Therapeutics, Inc. has an analysts' consensus of $10.30 which suggests that it could grow by 59.94%. Given that TransCode Therapeutics, Inc. has higher upside potential than Aquestive Therapeutics, Inc., analysts believe TransCode Therapeutics, Inc. is more attractive than Aquestive Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RNAZTransCode Therapeutics, Inc.0 0 0 AQSTAquestive Therapeutics, Inc.6 0 0 -
Is RNAZ or AQST More Risky?
TransCode Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Aquestive Therapeutics, Inc. has a beta of 1.590, suggesting its more volatile than the S&P 500 by 59.015%.
-
Which is a Better Dividend Stock RNAZ or AQST?
TransCode Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aquestive Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransCode Therapeutics, Inc. pays -- of its earnings as a dividend. Aquestive Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RNAZ or AQST?
TransCode Therapeutics, Inc. quarterly revenues are --, which are smaller than Aquestive Therapeutics, Inc. quarterly revenues of $12.8M. TransCode Therapeutics, Inc.'s net income of -$4.9M is higher than Aquestive Therapeutics, Inc.'s net income of -$15.4M. Notably, TransCode Therapeutics, Inc.'s price-to-earnings ratio is -- while Aquestive Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransCode Therapeutics, Inc. is -- versus 14.71x for Aquestive Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RNAZTransCode Therapeutics, Inc.-- -- -- -$4.9M AQSTAquestive Therapeutics, Inc.14.71x -- $12.8M -$15.4M
-
Which has Higher Returns RNAZ or LLY?
Eli Lilly & Co. has a net margin of -- compared to TransCode Therapeutics, Inc.'s net margin of 31.72%. TransCode Therapeutics, Inc.'s return on equity of -775.26% beat Eli Lilly & Co.'s return on equity of 106.26%.
Company Gross Margin Earnings Per Share Invested Capital RNAZTransCode Therapeutics, Inc.-- -$5.82 $1.4M LLYEli Lilly & Co.82.91% $6.21 $66.4B -
What do Analysts Say About RNAZ or LLY?
TransCode Therapeutics, Inc. has a consensus price target of $10.00, signalling upside risk potential of 3142.35%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,056.70 which suggests that it could grow by 4.16%. Given that TransCode Therapeutics, Inc. has higher upside potential than Eli Lilly & Co., analysts believe TransCode Therapeutics, Inc. is more attractive than Eli Lilly & Co..
Company Buy Ratings Hold Ratings Sell Ratings RNAZTransCode Therapeutics, Inc.0 0 0 LLYEli Lilly & Co.17 8 0 -
Is RNAZ or LLY More Risky?
TransCode Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.
-
Which is a Better Dividend Stock RNAZ or LLY?
TransCode Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.59% to investors and pays a quarterly dividend of $1.50 per share. TransCode Therapeutics, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RNAZ or LLY?
TransCode Therapeutics, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. TransCode Therapeutics, Inc.'s net income of -$4.9M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, TransCode Therapeutics, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 50.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransCode Therapeutics, Inc. is -- versus 15.57x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RNAZTransCode Therapeutics, Inc.-- -- -- -$4.9M LLYEli Lilly & Co.15.57x 50.17x $17.6B $5.6B
-
Which has Higher Returns RNAZ or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to TransCode Therapeutics, Inc.'s net margin of -255.85%. TransCode Therapeutics, Inc.'s return on equity of -775.26% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital RNAZTransCode Therapeutics, Inc.-- -$5.82 $1.4M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About RNAZ or NBY?
TransCode Therapeutics, Inc. has a consensus price target of $10.00, signalling upside risk potential of 3142.35%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -22.02%. Given that TransCode Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe TransCode Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RNAZTransCode Therapeutics, Inc.0 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is RNAZ or NBY More Risky?
TransCode Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock RNAZ or NBY?
TransCode Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. TransCode Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RNAZ or NBY?
TransCode Therapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. TransCode Therapeutics, Inc.'s net income of -$4.9M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, TransCode Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransCode Therapeutics, Inc. is -- versus 2.12x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RNAZTransCode Therapeutics, Inc.-- -- -- -$4.9M NBYNovaBay Pharmaceuticals, Inc.2.12x 1.83x $521K -$1.3M
-
Which has Higher Returns RNAZ or PTN?
Palatin Technologies has a net margin of -- compared to TransCode Therapeutics, Inc.'s net margin of --. TransCode Therapeutics, Inc.'s return on equity of -775.26% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital RNAZTransCode Therapeutics, Inc.-- -$5.82 $1.4M PTNPalatin Technologies-- -- -- -
What do Analysts Say About RNAZ or PTN?
TransCode Therapeutics, Inc. has a consensus price target of $10.00, signalling upside risk potential of 3142.35%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than TransCode Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than TransCode Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RNAZTransCode Therapeutics, Inc.0 0 0 PTNPalatin Technologies0 0 0 -
Is RNAZ or PTN More Risky?
TransCode Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock RNAZ or PTN?
TransCode Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransCode Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RNAZ or PTN?
TransCode Therapeutics, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. TransCode Therapeutics, Inc.'s net income of -$4.9M is higher than Palatin Technologies's net income of --. Notably, TransCode Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransCode Therapeutics, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RNAZTransCode Therapeutics, Inc.-- -- -- -$4.9M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns RNAZ or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to TransCode Therapeutics, Inc.'s net margin of --. TransCode Therapeutics, Inc.'s return on equity of -775.26% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital RNAZTransCode Therapeutics, Inc.-- -$5.82 $1.4M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About RNAZ or TOVX?
TransCode Therapeutics, Inc. has a consensus price target of $10.00, signalling upside risk potential of 3142.35%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 2797.35%. Given that TransCode Therapeutics, Inc. has higher upside potential than Theriva Biologics, Inc., analysts believe TransCode Therapeutics, Inc. is more attractive than Theriva Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RNAZTransCode Therapeutics, Inc.0 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is RNAZ or TOVX More Risky?
TransCode Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock RNAZ or TOVX?
TransCode Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransCode Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RNAZ or TOVX?
TransCode Therapeutics, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. TransCode Therapeutics, Inc.'s net income of -$4.9M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, TransCode Therapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransCode Therapeutics, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RNAZTransCode Therapeutics, Inc.-- -- -- -$4.9M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 18.9% over the past day.
